In vitro, triggering TLR9 with a TLR9 agonist (CpG ODN) was found to reduce cell proliferation and alter proinflammatory cytokines, thereby facilitating the inhibition of hormone receptor‐positive BC cells (T47D) and triple‐negative BC cells (MDA‐MB‐468).304. Here, NR4A1 is linked to breast cancer.